EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ALKBH3 suppresses ischemia/reperfusion‐induced PANoptosis by regulating the ZBED6/STAT1/AIM2 axis through m 1 A demethylation

Hongtao Diao, Chunlei Wang, Yuting Xiong, Qiaoyue Zhao, Xinyue Zhang, Xiaohui Qi, Yuan Zou, Jiaxuan Li, Linghua Zeng, Wei Si, Feng Zhang, Ping Pang und 3 weitere

Clinical and Translational Medicine · 2026-03 · 16 (3)

DOI: 10.1002/ctm2.70632 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 12.03.2026. Verfasst von Hongtao Diao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, China. Hauptthemen laut MEDLINE: STAT1 Transcription Factor, Myocardial Reperfusion Injury, DNA-Binding Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Research and Development Program of Heilongjiang, Department of Education, Heilongjiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Myocardial ischemia/reperfusion (I/R) injury induces an intense inflammatory response and involves multiple cell death pathways. PANoptosis, an integrated cell death process involving pyroptosis, apoptosis and necroptosis, is a major driver of cardiomyocyte loss during I/R injury. However, the epitranscriptomic control of PANoptosis is poorly understood.

Methods

We investigated the role of ALKBH3, an mRNA N 1 ‐methyladenosine (m 1 A) demethylase, in the regulation of cardiomyocyte PANoptosis using hypoxia/reoxygenation models in vitro and murine I/R models in vivo. Integrated transcriptomic and m 1 A epitranscriptomic profiling identified downstream targets. Loss‐ and gain‐of‐function studies of ALKBH3, AIM2, ZBED6 and STAT1 (siRNA or plasmid overexpression) were coupled with assessments of cell death phenotypes, inflammasome activity and gene expression. Molecular interactions and transcriptional/translational regulation were examined using co‐immunoprecipitation, chromatin immunoprecipitation (ChIP) and dual‐luciferase reporter assays.

Results

Cardiomyocyte‐restricted ALKBH3 overexpression mitigates I/R injury in vivo. Mechanistically, ALKBH3 acts as a key suppressor of PANoptosis by inhibiting AIM2. ALKBH3 demethylates m 1 A onZBED6 mRNA, enhancing ZBED6 translation and limiting cardiomyocyte PANoptosis. Although ZBED6 does not bind directly to the AIM2 promoter, it physically interacts with STAT1, a transcriptional activator of AIM2, and represses STAT1‐driven AIM2 expression. ZBED6 overexpression reduces AIM2 levels and PANoptosis, whereas AIM2 knockout attenuates the exacerbation of cardiac injury and PANoptosis induced by ALKBH3 silencing.

Conclusions

These findings identify the ALKBH3/ZBED6/STAT1/AIM2 signalling axis that epitranscriptomically breaks cardiomyocyte PANoptosis, highlighting a tractable therapeutic target that limits cell death and improves myocardial outcomes after I/R.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT1 Transcription FactorMyocardial Reperfusion InjuryDNA-Binding ProteinsAnimalsMiceMyocytes, CardiacDemethylationMice, Inbred C57BL

Stichwörter der Autor:innen

AIM2ALKBH3PANoptosism1A modification

Substanzen

STAT1 Transcription FactorDNA-Binding ProteinsStat1 protein, mouse

Autor:innen und Institutionen

  • Department of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, China.
  • Department of Pharmacology, the State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Key Laboratory of Cardiovascular Research, Ministry of Education, College of Pharmacy, Harbin Medical University, Ha…
  • Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Noncoding RNA, Institute for Frontier Medical Technology, College of Chemistry and Chemical Engineering, Shanghai University of Engineering S…

ORCID-Profile: Yu Bian, Baofeng Yang

Förderung

  • National Natural Science Foundation of China
  • Key Research and Development Program of Heilongjiang
  • Department of Education, Heilongjiang Province

Zitieren

APA

Diao, H., Wang, C., Xiong, Y., Zhao, Q., Zhang, X., Qi, X., Zou, Y., Li, J., Zeng, L., Si, W., Zhang, F., Pang, P., Wang, N., Bian, Y., & Yang, B. (2026). ALKBH3 suppresses ischemia/reperfusion‐induced PANoptosis by regulating the ZBED6/STAT1/AIM2 axis through m 1 A demethylation. Clinical and Translational Medicine, 16(3). https://doi.org/10.1002/ctm2.70632

Vancouver

Diao H, Wang C, Xiong Y, Zhao Q, Zhang X, Qi X, et al. ALKBH3 suppresses ischemia/reperfusion‐induced PANoptosis by regulating the ZBED6/STAT1/AIM2 axis through m 1 A demethylation. Clinical and Translational Medicine. 2026;16(3). doi:10.1002/ctm2.70632

BibTeX
@article{Diao2026,
  author = {Diao, Hongtao and Wang, Chunlei and Xiong, Yuting and Zhao, Qiaoyue and Zhang, Xinyue and Qi, Xiaohui and Zou, Yuan and Li, Jiaxuan and Zeng, Linghua and Si, Wei and Zhang, Feng and Pang, Ping and Wang, Ning and Bian, Yu and Yang, Baofeng},
  title = {ALKBH3 suppresses ischemia/reperfusion‐induced PANoptosis by regulating the ZBED6/STAT1/AIM2 axis through m 1 A demethylation},
  journal = {Clinical and Translational Medicine},
  year = {2026},
  volume = {16},
  number = {3},
  doi = {10.1002/ctm2.70632}
}
Kostenlos starten →